Antibody-Drug Conjugate– tag –
-
Xcellon Biologics Acquires NextCure’s 40,000-Square-Foot GMP Manufacturing Facility, Enhancing End-to-End CRDMO Capabilities for Next-Generation Bioconjugates and Complex Biologics
Outsourced Pharma USA Overview Xcellon Biologics has acquired NextCure's 40,000-square-foot GMP manufacturing facility, significantly bolstering its capabilities as an end-to-end CRDMO (Contract Research, Development, and Manufacturing O... -
Biopharmaceutical CDMO Capacity Crunch Persists, Driving Rapid Expansion in Cell and Gene Therapy Production
Contract Pharma USA Overview The biopharmaceutical industry continues to face a CDMO capacity crunch, prompting contract development and manufacturing organizations to heavily invest in expanding production capabilities, particularly for... -
Biologics and GLP-1 Agonists Drive Acceleration of Automation and Digitization in Fill-Finish Manufacturing
BioProcess Online USA Overview The rapid rise of biologics—including antibody-drug conjugates (ADCs), cell & gene therapies, and mRNA products—and GLP-1 receptor agonists is accelerating the evolution of fill-finish manufacturing pro... -
Xcellon Biologics Acquires NextCure GMP Facility, Establishes End-to-End CRDMO for Next-Gen Bioconjugates, Streamlining Development from Discovery to Clinical Supply
Outsourced Pharma USA Overview Xcellon Biologics has acquired a GMP manufacturing facility from NextCure, transforming into an end-to-end Contract Research, Development, and Manufacturing Organization (CRDMO) for next-generation bioconju... -
Eurofins CDMO Alphora Expands Kilolab and HPAPI Manufacturing, Strengthening Integrated ADC Development
Las Vegas Sun News (via Business Wire) USA Overview Eurofins CDMO Alphora has significantly expanded its kilolab and High Potency Active Pharmaceutical Ingredient (HPAPI) development and manufacturing capabilities at its Mississauga, Can... -
乳がん治療向け次世代ADCの開発課題と進歩：送達生物学の最適化が成功の鍵
PubMed (Expert Opinion on Drug Delivery) USA Overview Expert Opinion on Drug Deliveryに掲載されたレビューは、乳がんの治療抵抗性疾患に対する次世代抗体薬物複合体（ADC）の開発における進歩と課題を統合的に評価しました。本レビューは、ADCの設計... -
ADCs Take Center Stage at HerHealth2026: A Promising Strategy for Refractory Breast and Gynecological Cancers
HerHealth2026 USA Overview At the recent HerHealth2026 conference, Antibody-Drug Conjugates (ADCs) emerged as a pivotal topic, underscoring their growing importance in treating breast and gynecological cancers. These innovative therapies... -
BioRay Pharmaceutical Advances Novel Dual-Payload TROP2 ADC, BR113, into First-in-Human Clinical Trials
AllSci China Overview China's BioRay Pharmaceutical has initiated a first-in-human Phase I trial for BR113, an innovative dual-payload TROP2 antibody-drug conjugate (ADC) targeting patients with advanced solid tumors. BR113 distinguishes... -
AsymBio Secures $184M to Scale Biologics CDMO Capacity for Advanced Therapies like ADCs and Bispecific Antibodies
Megaproject China Overview Shanghai-based biologics CDMO AsymBio has successfully raised approximately $184 million (1.24 billion RMB) from investors including Asymchem Group and Hillhouse Qirui. This substantial investment will drive th... -
Next-Gen ADCs Show Transformative Efficacy: 46% ORR in Platinum-Resistant Gynecological Cancers, up to 50% ORR in Nasopharyngeal Cancer at AACR 2026
AACR Annual Meeting 2026 USA Overview The AACR Annual Meeting 2026 highlighted groundbreaking clinical results for next-generation Antibody-Drug Conjugates (ADCs), demonstrating significant advances in targeted cancer therapy. A combinat...
